rss
Br J Ophthalmol 91:161-165 doi:10.1136/bjo.2006.099887
  • Clinical science
    • Extended reports

Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia

  1. H Sakaguchi,
  2. Y Ikuno,
  3. F Gomi,
  4. M Kamei,
  5. M Sawa,
  6. M Tsujikawa,
  7. Y Oshima,
  8. S Kusaka,
  9. Y Tano
  1. Department of Ophthalmology, Osaka University Medical School, Suita, Japan
  1. Correspondence to: Y Ikuno Department of Ophthalmology, Osaka University Medical School, 2-2 Yamadaoka, E7, Suita, Osaka 565-0871, Japan; ikuno{at}ophthal.med.osaka-u.ac.jp
  • Accepted 31 July 2006
  • Published Online First 16 August 2006

Abstract

Aim: To assess the efficacy and safety of an intravitreal injection of bevacizumab (Avastin®) for myopic choroidal neovascularisation (mCNV).

Methods: Intravitreal bevacizumab (1 mg) was injected into eight eyes of eight patients with mCNV in this non-randomised, interventional case series. The best-corrected visual acuity (BCVA) was measured and the optical coherence tomography (OCT) and fluorescein angiography findings were examined before and after treatment. The minimum follow-up time was 3 months.

Results: The mean BCVA was 0.26 before treatment and 0.51 at the last visit (p = 0.009). The BCVA improved to two or more lines in six eyes (75%) and remained the same in two eyes (25%). Leakage from the mCNV on fluorescein angiography decreased in seven eyes (87.5%). The choroidal neovascularisation area on fluorescein angiography (p = 0.049) and the foveal thickness on OCT images decreased significantly (p = 0.027) after the treatment. No major complications developed.

Conclusion: Intravitreal injection of bevacizumab seems to be an effective and safe treatment for mCNV.

Footnotes

  • Published Online First 16 August 2006

  • This work was Supported by Health Sciences Research Grant from the Ministry of Health, Labor and Welfare, Japan. We have no proprietary interest in any aspect of this report.

  • Competing interests: None declared.